82 Result(s)

Article

Reply to “Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?”

Shozo Ohsumi in Breast Cancer (2023)

Article

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry

This subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese pa...

Shozo Ohsumi, Kenichi Watanabe, Naoto Kondo, Yoshimasa Kosaka… in Breast Cancer (2023)

Article

A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

Breast-conserving surgery with radiotherapy is one of standard treatments for early breast cancer. However, it is regarded as an option to treat elderly patients with small hormone receptor-positive breast can...

Shozo Ohsumi, Reiki Nishimura, Norikazu Masuda, Sadako Akashi-Tanaka… in Breast Cancer (2023)

Article

Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, Shinji Ohno… in Breast Cancer (2022)

Article

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institution...

Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, Shinji Ohno… in Breast Cancer (2022)

Article

Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

Su-** Koh, Shozo Ohsumi, Masato Takahashi, Eisuke Fukuma, Kyung Hae Jung… in Breast Cancer (2022)

Article

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

The multinational BREAKOUT study (NCT03078036) sought to determine the prevalence of germline BRCA1/2 (gBRCA1/2) and somatic BRCA1/2 (sBRCA1/2) mutations and mutations in other homologous recombination repair (HR...

Su-** Koh, Shozo Ohsumi, Masato Takahashi, Eisuke Fukuma, Kyung Hae Jung… in Breast Cancer (2022)

Article

Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers

Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance ima...

Megumi Takaoka, Shozo Ohsumi, Yuichiro Miyoshi, Mina Takahashi… in Surgical Case Reports (2021)

Article

Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer

The benefits of postoperative chemotherapy in patients with estrogen receptor (ER)-positive breast cancer remain unclear. The use of tumor grade, Ki-67, or ER expression failed to provide an accurate prognosis...

Fumine Tsukamoto, Koji Arihiro, Mina Takahashi, Ken-ichi Ito, Shozo Ohsumi… in BMC Cancer (2021)

Article

Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients

Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We...

Shozo Ohsumi, Sachiko Kiyoto, Mina Takahashi, Seiki Takashima… in Supportive Care in Cancer (2021)

Article

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

To evaluate the efficacies of cyclophosphamide, methotrexate, and fluorouracil (CMF) and tegafur–uracil (UFT) as adjuvant therapy in patients with resected stage I–IIIA breast cancer by immunohistochemistry (I...

Shinji Ohno, Shigehira Saji, Norikazu Masuda… in Breast Cancer Research and Treatment (2021)

Article

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (...

Joyce O’Shaughnessy, Christine Brezden-Masley, Marina Cazzaniga… in Breast Cancer Research (2020)

Article

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome

Panel sequencing of susceptibility genes for hereditary breast and ovarian cancer (HBOC) syndrome has uncovered numerous germline variants; however, their pathogenic relevance and ethnic diversity remain uncle...

Tomoko Kaneyasu, Seiichi Mori, Hideko Yamauchi, Shozo Ohsumi… in npj Breast Cancer (2020)

Article

Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study

The effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, has not been evaluated.

Hirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi… in British Journal of Cancer (2020)

Article

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

In PALOMA-2, palbociclib–letrozole significantly improved progression-free survival (PFS) vs placebo–letrozole in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/H...

Hirofumi Mukai, Chikako Shimizu… in International Journal of Clinical Oncology (2019)